ABVX is a readout-gated biotech with positive Phase 3 induction data, a much stronger cash position after the 2025 offering, and one big unresolved question: can obefazimod's maintenance data turn runway into a real ulcerative-colitis franchise?
Abivax (ABVX): the ulcerative-colitis readout that has to carry a EUR 530M runway
NASDAQABVXCoverage BootstrapBiotechnology
Thesis summary
ABVX is a readout-gated biotech with positive Phase 3 induction data, a much stronger cash position after the 2025 offering, and one big unresolved question: can obefazimod's maintenance data turn runway into a real ulcerative-colitis franchise?
View article
Discuss the thesis
0 commentsCommenting requires active membershipBecome a member
Attack the thesis, not the person.Add evidence when challenging claims.No pump, spam, or low-effort comments.
No comments yet. Start the discussion with evidence, a question, or a bear case.